Consequently, ADAMTS5 may be useful for diagnosing muscle pathology or monitoring the response to therapy in patients with established diagnoses, but is not capable of distinguishing between DMD, BMD and FSHD pathology. This evidence concerns the gene ADAMTS5 and facioscapulohumeral muscular dystrophy.